Primary Outcomes from a Randomized, Phase III Study of Belatacept vs Cyclosporine in Kidney Transplant Recipients (BENEFIT Study)
dc.contributor.author | Vincenti, Flavio | |
dc.contributor.author | Grinyo, Josep M. | |
dc.contributor.author | Charpentier, Bernard | |
dc.contributor.author | Pestana, Jose Osmar Medina [UNIFESP] | |
dc.contributor.author | Rostaing, Lionel | |
dc.contributor.author | Vanrenterghem, Yves | |
dc.contributor.author | Di Russo, Gregory B. | |
dc.contributor.author | Garg, Pushkal | |
dc.contributor.author | Lin, Chen-Sheng | |
dc.contributor.author | Larsen, Christian | |
dc.contributor.institution | Univ Calif San Francisco | |
dc.contributor.institution | Univ Hosp Bellvitge | |
dc.contributor.institution | Hop Bicetre | |
dc.contributor.institution | Universidade Federal de São Paulo (UNIFESP) | |
dc.contributor.institution | CHU Rangueil | |
dc.contributor.institution | Univ Hosp Kuleuven | |
dc.contributor.institution | Bristol Myers Squibb Co | |
dc.contributor.institution | Emory Univ | |
dc.date.accessioned | 2018-06-18T12:15:05Z | |
dc.date.available | 2018-06-18T12:15:05Z | |
dc.date.issued | 2009-08-01 | |
dc.description.affiliation | Univ Calif San Francisco, Transplant Ctr, San Francisco, CA 94143 USA | |
dc.description.affiliation | Univ Hosp Bellvitge, Div Nephrol, Barcelona, Spain | |
dc.description.affiliation | Hop Bicetre, Dept Nephrol, Le Kremlin Bicetre, France | |
dc.description.affiliation | Hosp Rim & Hipertensao Unifesp, Div Nephrol, Sao Paulo, Brazil | |
dc.description.affiliation | CHU Rangueil, Nephrol Dialysis & Multiorgan Transplant Unit, F-31054 Toulouse, France | |
dc.description.affiliation | Univ Hosp Kuleuven, Dept Nephrol, Louvain, Belgium | |
dc.description.affiliation | Bristol Myers Squibb Co, Immunol, Princeton, NJ USA | |
dc.description.affiliation | Emory Univ, Sch Med, Emory Transplant Ctr, Atlanta, GA USA | |
dc.description.affiliationUnifesp | Hosp Rim & Hipertensao Unifesp, Div Nephrol, Sao Paulo, Brazil | |
dc.description.source | Web of Science | |
dc.format.extent | 89-89 | |
dc.identifier | http://dx.doi.org/10.1111/j.1432-2277.2009.00961.x | |
dc.identifier.citation | Transplant International. Malden: Wiley-blackwell Publishing, Inc, v. 22, (Suppl s2), p. 89-89, O-331, 2009. | |
dc.identifier.doi | 10.1111/j.1432-2277.2009.00961.x | |
dc.identifier.issn | 0934-0874 | |
dc.identifier.uri | http://repositorio.unifesp.br/handle/11600/45681 | |
dc.identifier.wos | WOS:000269392800329 | |
dc.language.iso | eng | |
dc.publisher | Wiley-Blackwell | |
dc.relation.ispartof | Transplant International | |
dc.rights | Acesso aberto | |
dc.rights.license | http://olabout.wiley.com/WileyCDA/Section/id-406071.html | |
dc.title | Primary Outcomes from a Randomized, Phase III Study of Belatacept vs Cyclosporine in Kidney Transplant Recipients (BENEFIT Study) | en |
dc.type | Resumo |